Lipidomics Reveals Early Metabolic Changes in Subjects with Schizophrenia

Effects of Atypical Antipsychotics

Joseph Patrick McEvoy, Rebecca A. Baillie, Hongjie Zhu, Peter F Buckley, Matcheri S. Keshavan, Henry A. Nasrallah, George G. Dougherty, Jeffrey K. Yao, Rima Kaddurah-Daouk

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

There is a critical need for mapping early metabolic changes in schizophrenia to capture failures in regulation of biochemical pathways and networks. This information could provide valuable insights about disease mechanisms, trajectory of disease progression, and diagnostic biomarkers. We used a lipidomics platform to measure individual lipid species in 20 drug-naïve patients with a first episode of schizophrenia (FE group), 20 patients with chronic schizophrenia that had not adhered to prescribed medications (RE group), and 29 race-matched control subjects without schizophrenia. Lipid metabolic profiles were evaluated and compared between study groups and within groups before and after treatment with atypical antipsychotics, risperidone and aripiprazole. Finally, we mapped lipid profiles to n3 and n6 fatty acid synthesis pathways to elucidate which enzymes might be affected by disease and treatment. Compared to controls, the FE group showed significant down-regulation of several n3 polyunsaturated fatty acids (PUFAs), including 20:5n3, 22:5n3, and 22:6n3 within the phosphatidylcholine and phosphatidylethanolamine lipid classes. Differences between FE and controls were only observed in the n3 class PUFAs; no differences where noted in n6 class PUFAs. The RE group was not significantly different from controls, although some compositional differences within PUFAs were noted. Drug treatment was able to correct the aberrant PUFA levels noted in FE patients, but changes in re patients were not corrective. Treatment caused increases in both n3 and n6 class lipids. These results supported the hypothesis that phospholipid n3 fatty acid deficits are present early in the course of schizophrenia and tend not to persist throughout its course. These changes in lipid metabolism could indicate a metabolic vulnerability in patients with schizophrenia that occurs early in development of the disease.

Original languageEnglish (US)
Article numbere68717
JournalPloS one
Volume8
Issue number7
DOIs
StatePublished - Jul 24 2013

Fingerprint

Antipsychotic Agents
Schizophrenia
Unsaturated Fatty Acids
Omega-3 Fatty Acids
polyunsaturated fatty acids
Lipids
lipids
drug therapy
Drug therapy
Risperidone
fatty acids
Biomarkers
Phosphatidylcholines
Metabolome
phosphatidylethanolamines
Therapeutics
Phospholipids
Lipid Metabolism
disease course
phosphatidylcholines

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

McEvoy, J. P., Baillie, R. A., Zhu, H., Buckley, P. F., Keshavan, M. S., Nasrallah, H. A., ... Kaddurah-Daouk, R. (2013). Lipidomics Reveals Early Metabolic Changes in Subjects with Schizophrenia: Effects of Atypical Antipsychotics. PloS one, 8(7), [e68717]. https://doi.org/10.1371/journal.pone.0068717

Lipidomics Reveals Early Metabolic Changes in Subjects with Schizophrenia : Effects of Atypical Antipsychotics. / McEvoy, Joseph Patrick; Baillie, Rebecca A.; Zhu, Hongjie; Buckley, Peter F; Keshavan, Matcheri S.; Nasrallah, Henry A.; Dougherty, George G.; Yao, Jeffrey K.; Kaddurah-Daouk, Rima.

In: PloS one, Vol. 8, No. 7, e68717, 24.07.2013.

Research output: Contribution to journalArticle

McEvoy, JP, Baillie, RA, Zhu, H, Buckley, PF, Keshavan, MS, Nasrallah, HA, Dougherty, GG, Yao, JK & Kaddurah-Daouk, R 2013, 'Lipidomics Reveals Early Metabolic Changes in Subjects with Schizophrenia: Effects of Atypical Antipsychotics', PloS one, vol. 8, no. 7, e68717. https://doi.org/10.1371/journal.pone.0068717
McEvoy, Joseph Patrick ; Baillie, Rebecca A. ; Zhu, Hongjie ; Buckley, Peter F ; Keshavan, Matcheri S. ; Nasrallah, Henry A. ; Dougherty, George G. ; Yao, Jeffrey K. ; Kaddurah-Daouk, Rima. / Lipidomics Reveals Early Metabolic Changes in Subjects with Schizophrenia : Effects of Atypical Antipsychotics. In: PloS one. 2013 ; Vol. 8, No. 7.
@article{d08b7d7447cd445ea0bfa4255f6542c1,
title = "Lipidomics Reveals Early Metabolic Changes in Subjects with Schizophrenia: Effects of Atypical Antipsychotics",
abstract = "There is a critical need for mapping early metabolic changes in schizophrenia to capture failures in regulation of biochemical pathways and networks. This information could provide valuable insights about disease mechanisms, trajectory of disease progression, and diagnostic biomarkers. We used a lipidomics platform to measure individual lipid species in 20 drug-na{\"i}ve patients with a first episode of schizophrenia (FE group), 20 patients with chronic schizophrenia that had not adhered to prescribed medications (RE group), and 29 race-matched control subjects without schizophrenia. Lipid metabolic profiles were evaluated and compared between study groups and within groups before and after treatment with atypical antipsychotics, risperidone and aripiprazole. Finally, we mapped lipid profiles to n3 and n6 fatty acid synthesis pathways to elucidate which enzymes might be affected by disease and treatment. Compared to controls, the FE group showed significant down-regulation of several n3 polyunsaturated fatty acids (PUFAs), including 20:5n3, 22:5n3, and 22:6n3 within the phosphatidylcholine and phosphatidylethanolamine lipid classes. Differences between FE and controls were only observed in the n3 class PUFAs; no differences where noted in n6 class PUFAs. The RE group was not significantly different from controls, although some compositional differences within PUFAs were noted. Drug treatment was able to correct the aberrant PUFA levels noted in FE patients, but changes in re patients were not corrective. Treatment caused increases in both n3 and n6 class lipids. These results supported the hypothesis that phospholipid n3 fatty acid deficits are present early in the course of schizophrenia and tend not to persist throughout its course. These changes in lipid metabolism could indicate a metabolic vulnerability in patients with schizophrenia that occurs early in development of the disease.",
author = "McEvoy, {Joseph Patrick} and Baillie, {Rebecca A.} and Hongjie Zhu and Buckley, {Peter F} and Keshavan, {Matcheri S.} and Nasrallah, {Henry A.} and Dougherty, {George G.} and Yao, {Jeffrey K.} and Rima Kaddurah-Daouk",
year = "2013",
month = "7",
day = "24",
doi = "10.1371/journal.pone.0068717",
language = "English (US)",
volume = "8",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "7",

}

TY - JOUR

T1 - Lipidomics Reveals Early Metabolic Changes in Subjects with Schizophrenia

T2 - Effects of Atypical Antipsychotics

AU - McEvoy, Joseph Patrick

AU - Baillie, Rebecca A.

AU - Zhu, Hongjie

AU - Buckley, Peter F

AU - Keshavan, Matcheri S.

AU - Nasrallah, Henry A.

AU - Dougherty, George G.

AU - Yao, Jeffrey K.

AU - Kaddurah-Daouk, Rima

PY - 2013/7/24

Y1 - 2013/7/24

N2 - There is a critical need for mapping early metabolic changes in schizophrenia to capture failures in regulation of biochemical pathways and networks. This information could provide valuable insights about disease mechanisms, trajectory of disease progression, and diagnostic biomarkers. We used a lipidomics platform to measure individual lipid species in 20 drug-naïve patients with a first episode of schizophrenia (FE group), 20 patients with chronic schizophrenia that had not adhered to prescribed medications (RE group), and 29 race-matched control subjects without schizophrenia. Lipid metabolic profiles were evaluated and compared between study groups and within groups before and after treatment with atypical antipsychotics, risperidone and aripiprazole. Finally, we mapped lipid profiles to n3 and n6 fatty acid synthesis pathways to elucidate which enzymes might be affected by disease and treatment. Compared to controls, the FE group showed significant down-regulation of several n3 polyunsaturated fatty acids (PUFAs), including 20:5n3, 22:5n3, and 22:6n3 within the phosphatidylcholine and phosphatidylethanolamine lipid classes. Differences between FE and controls were only observed in the n3 class PUFAs; no differences where noted in n6 class PUFAs. The RE group was not significantly different from controls, although some compositional differences within PUFAs were noted. Drug treatment was able to correct the aberrant PUFA levels noted in FE patients, but changes in re patients were not corrective. Treatment caused increases in both n3 and n6 class lipids. These results supported the hypothesis that phospholipid n3 fatty acid deficits are present early in the course of schizophrenia and tend not to persist throughout its course. These changes in lipid metabolism could indicate a metabolic vulnerability in patients with schizophrenia that occurs early in development of the disease.

AB - There is a critical need for mapping early metabolic changes in schizophrenia to capture failures in regulation of biochemical pathways and networks. This information could provide valuable insights about disease mechanisms, trajectory of disease progression, and diagnostic biomarkers. We used a lipidomics platform to measure individual lipid species in 20 drug-naïve patients with a first episode of schizophrenia (FE group), 20 patients with chronic schizophrenia that had not adhered to prescribed medications (RE group), and 29 race-matched control subjects without schizophrenia. Lipid metabolic profiles were evaluated and compared between study groups and within groups before and after treatment with atypical antipsychotics, risperidone and aripiprazole. Finally, we mapped lipid profiles to n3 and n6 fatty acid synthesis pathways to elucidate which enzymes might be affected by disease and treatment. Compared to controls, the FE group showed significant down-regulation of several n3 polyunsaturated fatty acids (PUFAs), including 20:5n3, 22:5n3, and 22:6n3 within the phosphatidylcholine and phosphatidylethanolamine lipid classes. Differences between FE and controls were only observed in the n3 class PUFAs; no differences where noted in n6 class PUFAs. The RE group was not significantly different from controls, although some compositional differences within PUFAs were noted. Drug treatment was able to correct the aberrant PUFA levels noted in FE patients, but changes in re patients were not corrective. Treatment caused increases in both n3 and n6 class lipids. These results supported the hypothesis that phospholipid n3 fatty acid deficits are present early in the course of schizophrenia and tend not to persist throughout its course. These changes in lipid metabolism could indicate a metabolic vulnerability in patients with schizophrenia that occurs early in development of the disease.

UR - http://www.scopus.com/inward/record.url?scp=84880833108&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880833108&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0068717

DO - 10.1371/journal.pone.0068717

M3 - Article

VL - 8

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 7

M1 - e68717

ER -